<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04906772</url>
  </required_header>
  <id_info>
    <org_study_id>FAMSU R 21</org_study_id>
    <nct_id>NCT04906772</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine-ketamine Versus Propofol-ketamine for Sedation During Endoscopy in Hepatic Patients</brief_title>
  <official_title>Dexmedetomidine-ketamine Versus Propofol-ketamine for Sedation During Upper Gastro-intestinal Endoscopy in Hepatic Patients (a Comparative Randomized Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tamer Nabil Abdelrahman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim to compare the response to ketamine/dexmedetomidine and ketamine/propofol combinations&#xD;
      used in hepatic patients with child-Pugh classification (class A), and early (class B)&#xD;
      undergoing UGIE.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      70 Patients will be randomly allocated into two groups; Group (KD): Ketamine/dexmedetomidine&#xD;
      (35 patients), will receive IV ketamine 0.25mg/kg and dexmedetomidine1µg/kg over 10 min as&#xD;
      loading followed by dexmedetomidine infusion with a rate of 0.5µg/kg/hr and Group (KP):&#xD;
      ketamine/propofol (35 patients) will receive IV ketamine 0.25 mg/kg loading and propofol 1&#xD;
      mg/kg over 10 min followed by propofol infusion with a rate of 0.5 mg/kg/hr as a control&#xD;
      group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 3, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 13, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>induction time</measure>
    <time_frame>after 5 minutes from the start of drug infusion till target Ramsay Sedation Score ≥ 3 is reached</time_frame>
    <description>Time to reach target Ramsay Sedation Score ≥ 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recovery time</measure>
    <time_frame>after 10 minutes from the stoppage of drug infusion at the end of the procedure till spontaneous eye opening</time_frame>
    <description>time from the stoppage of drug infusion at the end of the procedure till spontaneous eye opening</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Anesthesia; Reaction</condition>
  <arm_group>
    <arm_group_label>Group KD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants received loading of ketamine 1 mg/kg and dexmedetomidine 1µg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr ketamine and 0.25µg/kg/hr dexmedetomidine throughout the procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group KP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>participants received loading of ketamine 1 mg/kg and propofol 1 mg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr propofol and 0.25 µg/kg/hr dexmedetomidine throughout the procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>participants received loading of ketamine 1 mg/kg and dexmedetomidine 1µg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr ketamine and 0.25µg/kg/hr dexmedetomidine throughout the procedure.</description>
    <arm_group_label>Group KD</arm_group_label>
    <other_name>ketamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>participants received loading of ketamine 1 mg/kg and propofol 1mg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr propofol and 0.25µg/kg/hr dexmedetomidine throughout the procedure.</description>
    <arm_group_label>Group KP</arm_group_label>
    <other_name>ketamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  hepatic patients with child-Pugh classification (class A), and (class B)&#xD;
&#xD;
          -  American Society of Anesthesiologists physical status II, III&#xD;
&#xD;
          -  aged 18 to 60 years&#xD;
&#xD;
          -  scheduled for elective Upper gastro-intestinal endoscopy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  emergency gastro-intestinal endoscopy.&#xD;
&#xD;
          -  patients with severe hepatic disorder (Child C) ,&#xD;
&#xD;
          -  chronic neuro-psychiatric disorder,&#xD;
&#xD;
          -  history of neuro-psychiatric drug intake,&#xD;
&#xD;
          -  severe cardiovascular diseases,&#xD;
&#xD;
          -  pregnancy,&#xD;
&#xD;
          -  history of drug abuse, and&#xD;
&#xD;
          -  history of allergy to any of the used drugs in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of medicine, Ain-Shams university</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Tamer Nabil Abdelrahman</investigator_full_name>
    <investigator_title>lecturer of anaesthesia, intensive care and pain management</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

